NCT05614752View on ClinicalTrials.gov

Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab

CompletedOBSERVATIONAL
Enrollment

10,067

Participants

Timeline

Start Date

July 6, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

November 8, 2024

Conditions
Gastroesophageal Reflux Disease
Interventions
DRUG

Fexuprazan

Fexuclue Tablet 40mg

Trial Locations (1)

Unknown

Jeonbuk National University Hospital, Jeonju

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY